| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_790467c977f27a27611438e90811e617 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-39 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0642 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0787
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 |
| filingDate |
1994-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1999-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00c54edb1b7ae8d0ad83837b34d2e953
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f923bdda1ef97dc5af3c74554f7cf1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_036d6c676c62f6165986dae9c240be1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83b6ac0f2df6b95b0902713163799c55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_727b0fb0bf3f7dd08bf758ee9635d3be |
| publicationDate |
1999-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5955357-A |
| titleOfInvention |
In-vitro-derived human neutrophil precursor cells |
| abstract |
The present invention provides a composition of human neutrophil precursor cells having at least 37% myeloblasts and promyeloblasts. Also provided are hematopoietic cell suspensions that have human neutrophil precursor cells and at least one hematopoietic growth factor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007196911-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-10019601-B4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10545135-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6350313-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-10019601-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9134299-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9804151-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8900861-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004076617-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9488643-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9482660-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8592208-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9383349-B2 |
| priorityDate |
1992-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |